Pharmaceutical Administration and Regulations in Japan - Nihs
Pharmaceutical Administration and Regulations in Japan - Nihs
Pharmaceutical Administration and Regulations in Japan - Nihs
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
The necessary measures so that<br />
appropriate treatment can be<br />
given to subjects when adverse<br />
events occur must be taken<br />
beforeh<strong>and</strong>.<br />
• The <strong>in</strong>vestigator must prepare the<br />
proper case report forms as<br />
specified <strong>in</strong> the protocol, etc. <strong>and</strong><br />
sign or seal them.<br />
• When deaths suspected of be<strong>in</strong>g<br />
caused by adverse reactions of<br />
the <strong>in</strong>vestigational product or<br />
other serious adverse events<br />
occur, the <strong>in</strong>vestigator must<br />
immediately report this to the<br />
director of the medical <strong>in</strong>stitution<br />
perform<strong>in</strong>g the trial <strong>and</strong> <strong>in</strong>form the<br />
sponsor or the person supplied<br />
with the <strong>in</strong>vestigational product<br />
when the trial is<br />
<strong>in</strong>vestigator-<strong>in</strong>itiated.<br />
4) Provisions concern<strong>in</strong>g <strong>in</strong>formed<br />
consent of subjects (Articles 50 to<br />
55)<br />
• When a prospective subject is<br />
asked to participate <strong>in</strong> a cl<strong>in</strong>ical<br />
trial, the <strong>in</strong>vestigator must<br />
appropriately expla<strong>in</strong> the contents<br />
of the cl<strong>in</strong>ical trial <strong>and</strong> other<br />
matters beforeh<strong>and</strong> to the subject<br />
us<strong>in</strong>g "written <strong>in</strong>formation"<br />
conta<strong>in</strong><strong>in</strong>g required items, <strong>and</strong><br />
obta<strong>in</strong> the written consent of the<br />
<strong>Pharmaceutical</strong> <strong>Regulations</strong> <strong>in</strong> <strong>Japan</strong>:<br />
subject.<br />
• The <strong>in</strong>vestigator mak<strong>in</strong>g the<br />
explanation <strong>and</strong> the prospective<br />
subject must date <strong>and</strong> sign or seal<br />
the consent form to make the<br />
consent effective.<br />
Chapter 5: St<strong>and</strong>ards concern<strong>in</strong>g<br />
reexam<strong>in</strong>ation data (Article 56)<br />
GCP st<strong>and</strong>ards also apply to the<br />
collection <strong>and</strong> preparation of data<br />
concern<strong>in</strong>g the results of<br />
post-market<strong>in</strong>g cl<strong>in</strong>ical trials to be<br />
submitted for reexam<strong>in</strong>ations or<br />
reevaluations, but tak<strong>in</strong>g account of<br />
the nature of post-market<strong>in</strong>g cl<strong>in</strong>ical<br />
trials, certa<strong>in</strong> provisions for cl<strong>in</strong>ical<br />
trials for new drug application are<br />
applied to those for reexam<strong>in</strong>ation<br />
<strong>and</strong> the required changes <strong>in</strong> read<strong>in</strong>g<br />
shall be made accord<strong>in</strong>gly <strong>in</strong> this<br />
article.<br />
Chapter 6: St<strong>and</strong>ards concern<strong>in</strong>g<br />
sponsor<strong>in</strong>g of cl<strong>in</strong>ical trials (Article<br />
57 to 59)<br />
These GCP st<strong>and</strong>ards also<br />
conta<strong>in</strong> provisions concern<strong>in</strong>g the<br />
acts of prospective sponsors of<br />
cl<strong>in</strong>ical trials or persons conduct<strong>in</strong>g<br />
the cl<strong>in</strong>ical trials (Article 57),<br />
<strong>in</strong>stitutions requested to perform<br />
cl<strong>in</strong>ical trials (Article 58) <strong>and</strong> cl<strong>in</strong>ical<br />
2011-3 - 105 -